Access and reimbursement pathways for digital health solutions and IVD devices

Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges

News
Published on:
February 21, 2023

Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular attention is paid to software-based in vitro diagnostics (IVDs). With this point of view, a strong connection between DTx and IVDs is observed.

The recent paper “Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges” investigates the current regulatory scenarios and reimbursement approaches adopted for DTx and IVDs.

The initial assumption was that countries apply different regulations for the access to the market and adopt different reimbursement systems for both DTx and IVDs. The final aim was to provide a general comparative overview and identify those aspects that should be better addressed to support the adoption and commercialization of DTx and IVDs.

The paper “Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges” is co-authored by Andrea Mantovani, Claudia Leopaldi, and Cassandra Maria Nighswander from Alira Health and Rossella Di Bidino, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Graduate School of Health Economics and Management (ALTEMS).

Related news

Blog March 20, 2023
The State of Market Access in Italy 2023
To learn about the state of market access in Italy today, we spoke with Giovanni Firenze, Director of Market Access Italy for Alira Health, who attended the recent 2023 Conferenza Nazionale(...)
Drug Development Market Access Pharma
Events March 6, 2023
World EPA Congress 2023
We are pleased to share that we will be participating in World EPA Congress 2023 as speakers and sponsors. World Evidence, Pricing and Access Congress is Europe’s largest congress(...)
Biotech Market Access Pharma Real-World Evidence
Blog March 6, 2023
Market Access in Catalonia: 2022 Trends and What’s Next
Alira Health contributed to the recently published 2022 BioRegion Report, the most extensive analysis of the assets, achievements, and trends in the life sciences and healthcare sector(...)
Biotech Market Access MedTech
Events February 21, 2023
sTARTUp Day 2023
We are pleased to announce that we will be joining sTARTUp Day 2023 as speakers. This unique event will bring together startup-minded people to celebrate entrepreneurship in the city of Tartu.
Healthcare Technology Market Access Spain Startups
News February 21, 2023
Access and reimbursement pathways for digital health solutions and IVD devices
Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular(...)
Diagnotics Digital Therapeutics Market Access Regulatory
Publications February 15, 2023
Position Paper: Enhancing Patients’ Access to Advanced Diagnostics
Alira Health and EUCOPE have teamed up to create a position paper outlining three key recommendations to enhance the advanced diagnostics ecosystem in France.
Diagnotics Patient Engagement
News February 13, 2023
Alira Health Contributes to 2022 Bioregion Report on the Future of Catalan Life Sciences
We are pleased to announce that Alira Health is a key contributor to the just released 2022 Bioregion Report, the benchmark study that analyzes the life sciences and healthcare sector in Catalonia.
Market Access
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.